Drug company issues warning about flu drugBMJ 2000; 320 doi: https://doi.org/10.1136/bmj.320.7231.334/b (Published 05 February 2000) Cite this as: BMJ 2000;320:334
- Gavin Yamey
GlaxoWellcome issued a warning letter to doctors across Europe last week that its drug for treating influenza, zanamivir (Relenza), could cause bronchospasm and serious respiratory deterioration.
The company now advises doctors to use special caution in prescribing the drug to patients with underlying asthma or chronic obstructive pulmonary disease. Such patients, it suggests, should …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial